je.st
news
Tag: mercks
Merck Receives Complete Response Letter for Suvorexant, Mercks Investigational Medicine for Insomnia
2013-07-01 14:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the company has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application for suvorexant, Mercks investigational medicine for the treatment of insomnia. In the Complete Response Letter, the FDA advised Merck that: Language: English Contact: MerckMedia Contacts:Steve Cragle, 415-845-1256orTracy Ogden, 267-305-2301orInvestor Contacts:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: complete
response
letter
medicine
Merck's Pharmaceutical Packaging Facility, Hangzhou
2013-06-05 01:00:00| Packaging Gateway
Global healthcare company Merck opened a new drug packaging facility in Hangzhou, China, in April 2013.
Tags: facility
packaging
pharmaceutical
hangzhou
GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant], Mercks HPV Vaccine, Available to Developing Countries through UNICEF Tender
2013-05-09 13:20:00| Merck.com - Product News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the company has been awarded a significant portion of the UNICEF human papillomavirus (HPV) vaccine tender, and will provide sustained supply of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] to GAVI-eligible countries. This agreement follows the GAVI Alliances earlier announcement that HPV vaccines would be included in its portfolio for the first time. Language: English Contact HTML: MerckMedia:Pamela Eisele, 908-423-5042orImraan Munshi, 215-652-0059orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
FDA Approves Mercks LIPTRUZET (ezetimibe and atorvastatin), a New Product That Can Help Powerfully Lower LDL Cholesterol
2013-05-03 21:06:15| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. LIPTRUZET Approved for Patients with Primary or Mixed Hyperlipidemia, as an Adjunct to Diet When Diet Alone Is Not Enough Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved LIPTRUZET(ezetimibe and atorvastatin) tablets for the treatment of elevated low-density lipoprotein (LDL) cholesterol in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet when diet alone is not enough. Language: English Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: product
lower
cholesterol
fda
Generic competition cuts Merck's Q1 sales, profit
2013-05-01 15:04:39| Biotech - Topix.net
Drugmaker Merck & Co. on Wednesday reported lower first-quarter results and cut its 2013 profit forecast by 15 cents a share.
Tags: sales
profit
competition
generic
Sites : [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] next »